Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
AVITA Medical, Inc. is a commercial-stage regenerative medicine company focused on developing and commercializing therapies for skin restoration. The company operates within the biotechnology and medical device industries, with a primary emphasis on acute wound care, particularly the treatment of severe burns and full-thickness skin defects. Its core product is the RECELL® System, a point-of-care device that enables clinicians to prepare autologous skin cell suspensions for application directly at the patient’s bedside, reducing the need for traditional skin grafting.
The company generates the majority of its revenue from sales of the RECELL® System and related consumables to hospitals and burn centers. AVITA Medical’s key customers include burn units, trauma centers, and surgeons specializing in reconstructive and plastic surgery. Its strategic positioning is based on clinically validated outcomes, reduced donor site morbidity, and the ability to treat large wound areas with minimal donor skin. AVITA Medical was originally founded in Australia in the late 1990s, later relocating its corporate headquarters to the United States as it transitioned from development-stage research to commercial operations following U.S. FDA approvals.
Business Operations
AVITA Medical operates primarily through a single reportable business segment focused on the development, manufacturing, and commercialization of autologous cell harvesting and delivery technologies. Revenue is generated through the sale of the RECELL® System, disposable kits, and procedure-based utilization within hospital settings. The company maintains integrated capabilities across product development, regulatory affairs, clinical research, manufacturing oversight, and direct sales.
Operations are concentrated in the United States, which represents the company’s largest commercial market, supported by regulatory approvals from the U.S. Food and Drug Administration. International operations include distribution activities in Europe and Asia-Pacific, primarily through third-party distributors. AVITA Medical does not publicly disclose material joint ventures but relies on manufacturing partners and clinical collaborators to support its supply chain and ongoing clinical studies.
Strategic Position & Investments
AVITA Medical’s strategic direction centers on expanding the clinical indications and adoption of the RECELL® System beyond severe burns into broader wound care, including soft tissue reconstruction and trauma-related skin defects. Growth initiatives include increased penetration of U.S. burn centers, expanded surgeon training programs, and ongoing clinical trials aimed at label expansion and reimbursement support.
The company has invested significantly in post-market clinical studies and health economics research to demonstrate cost-effectiveness and improved patient outcomes. While AVITA Medical has not completed major transformative acquisitions in recent years, it continues to invest in internal research and development to enhance its core technology platform. Emerging areas of focus include pediatric burn treatment and combination use of RECELL® with other wound care technologies.
Geographic Footprint
AVITA Medical is headquartered in Valencia, California, and conducts the majority of its commercial operations in North America. The United States represents its most significant revenue-generating region, driven by established reimbursement pathways and widespread adoption in accredited burn centers.
Internationally, the company maintains a presence in Europe, Australia, and parts of Asia-Pacific through distribution agreements and regulatory approvals. While international revenue currently represents a smaller portion of total sales, these regions are considered strategically important for long-term growth and clinical adoption. AVITA Medical’s historical roots in Australia continue to influence its clinical research and regulatory experience outside the U.S.
Leadership & Governance
AVITA Medical is led by an executive team with experience across medical devices, biotechnology, and commercial healthcare operations. The leadership emphasizes disciplined execution, clinical evidence generation, and expanding access to regenerative therapies through regulatory and reimbursement alignment.
Key executives include:
- James Corbett – President and Chief Executive Officer
- Michael Perry – Chief Financial Officer
- Jim Dale – Chief Commercial Officer
- Alfonso Chavez – Chief Operating Officer
- Andrew Quick – Chief Legal and Compliance Officer
The company is governed by a board of directors with backgrounds in healthcare, finance, and medical technology, supporting a strategic vision centered on sustainable growth, regulatory compliance, and long-term shareholder value.